Literature DB >> 8673532

Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study.

W W Wiebel1, A Jimenez, W Johnson, L Ouellet, B Jovanovic, T Lampinen, J Murray, M U O'Brien.   

Abstract

We monitored trends in HIV risk behaviors and seroconversion among out-of-treatment injection drug users (IDUs) receiving street-based outreach intervention. Beginning in 1988, 641 HIV-seronegative IDUs were recruited by targeted sampling methods to reflect broader IDU populations and were followed for 4 years (1988-1992). All were active injectors not in treatment when recruited. Cohort members were targets of HIV-prevention outreach. The intervention was guided by the Indigenous Leader Outreach Model: Exaddicts deliver HIV-prevention services targeting IDU social networks in community settings. Primary outcome measures were HIV seroconversion and HIV risk behaviors. Observed incidence of HIV infection decreased, from 8.4 to 2.4 per 100 person-years. Prevalence of drug risk behaviors also decreased, from 100 to 14%. Seroconversion was associated with injection risk behavior [risk ratio (RR) = 9.8]. Sex risk behavior also decreased, but less dramatically, from 71 to 45%. Out-of-treatment IDUs in Chicago have reduced their rates of new HIV infection by reducing their injection risk behavior. New infections were strongly associated with injection risk behavior but not with sex risk behavior.

Entities:  

Mesh:

Year:  1996        PMID: 8673532     DOI: 10.1097/00042560-199607000-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  25 in total

1.  Characteristics and utilization patterns of needle-exchange attendees in Chicago: 1994-1998.

Authors:  H Brahmbhatt; D Bigg; S A Strathdee
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

2.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 3.  Toward a comprehensive approach to HIV prevention for people who use drugs.

Authors:  Brandon D L Marshall; Evan Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 4.  HIV prevention with drug-using populations--current status and future prospects: introduction and overview.

Authors:  R H Needle; S L Coyle; J Normand; E Lambert; H Cesari
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 5.  Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States.

Authors:  Scott S Santibanez; Richard S Garfein; Andrea Swartzendruber; David W Purcell; Lynn A Paxton; Alan E Greenberg
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

6.  High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.

Authors:  Basmattee Boodram; Anna L Hotton; Louis Shekhtman; Alexander Gutfraind; Harel Dahari
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

7.  Sex, drugs, and HIV: does methadone maintenance reduce drug use and risky sexual behavior?

Authors:  C M Lollis; H S Strothers; D D Chitwood; M McGhee
Journal:  J Behav Med       Date:  2000-12

Review 8.  Outreach-based HIV prevention for injecting drug users: a review of published outcome data.

Authors:  S L Coyle; R H Needle; J Normand
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

9.  Preventing HIV in injection drug users: choosing the best mix of interventions for the population.

Authors:  Amy R Wilson; James G Kahn
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

10.  Social network influences on male and female condom use among women attending family planning clinics in the United States.

Authors:  Kyung-Hee Choi; Steven E Gregorich
Journal:  Sex Transm Dis       Date:  2009-12       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.